Kodiak Sciences stock saw significant rise over 150% at the opening bell after its drugs successfully passed a key trial. The stock continued to rise, doubling in value as the new eye disease drug matched Eylea in a phase 3 trial. Additional reports indicated the stock gained 172% as Kodiak's drugs targeted Regeneron's Eylea. The company's stock price exploded toward $100 following strong phase 3 DAYBREAK trial data for wet AMD.
More Top Stories
New Plan Proposed by Thames Water Creditors
Thames Water creditors have presented an updated plan for rescue. MPs have urged the government to step in. Sm...
NHL waivers see 61 players listed
NHL teams have placed 61 players on waivers ahead of the regular season. The Ottawa Senators and Montréal Cana...
Surcharge ban impacts Australian banking sector
Banks in Australia are modifying their rewards programs and discontinuing free travel insurance due to a surch...
A man is accused of first-degree murder in Alberta
A man has been charged with first degree murder. This follows a deadly shooting in the northern region of Albe...
Residents of Saint-Lô express distress after vehicles are set ablaze in city center
Residents of Saint Lô are upset after multiple vehicles were intentionally burned in the city center. The fire...
Emmerdale Confirms Billy Fletcher's Exit
Emmerdale has announced Billy Fletcher's fate amid departure fears. A brutal attack on Vinny Dingle was broadc...
Weekly Review · Weekly Review · Latest Update · Weekly Review · Latest Update · News Roundup · Weekly Review · News Roundup · Latest Update · Local Briefing · News Roundup · Weekly Review · Weekly Review · News Roundup · Weekly Review · Weekly Review · Community Report · Weekly Review · Local Briefing · Daily Digest · Weekly Review · Community Report · News Roundup · Local Briefing · Community Report · Weekly Review · Daily Digest · News Roundup · Local Briefing · News Roundup · Weekly Review · Weekly Review · News Roundup · News Roundup · News Roundup · News Roundup · Daily Digest · Daily Digest · Community Report · Weekly Review